Concepedia

Chengzi I. Kaku

CI

12

Publications

1.1K

Citations

12

H-Index

2020

Active since

Affiliations

Adimab (United States)(Current)

Scripps Research Institute

Ragon Institute of MGH, MIT and Harvard

International AIDS Vaccine Initiative

Dartmouth College

Chengzi I. Kaku is an author at Adimab (United States) specializing in vaccination, immunotherapy, and virology.

ORCID

Top concepts

Publications per year

2020–2024

12

Publications

12

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

C. Garrett Rappazzo, Longping V. Tse, Chengzi I. Kaku et al. · Science · 2021 · 382 citations · Full text

Prolonged evolution of the human B cell response to SARS-CoV-2 infection

Mrunal Sakharkar, C. Garrett Rappazzo, Wendy Wieland‐Alter et al. · Science Immunology · 2021 · 199 citations · Full text

Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection

Chengzi I. Kaku, Alan Bergeron, Clas Ahlm et al. · Science Immunology · 2022 · 141 citations · Full text

Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination

Chengzi I. Kaku, Elizabeth Champney, Johan Normark et al. · Science · 2022 · 79 citations · Full text

A broad and potent neutralization epitope in SARS-related coronaviruses

Meng Yuan, Xueyong Zhu, Wanting He et al. · Proceedings of the National Academy of Sciences · 2022 · 77 citations · Full text

, , +12

Rows per page

1–5 of 12